Quantcast

Industry news that matters to you.  Learn more

Global Standardization for Alzheimer’s Biomarkers Moves a Major Step Closer to Reality

Citeline, an Informa business unit, and the world’s leading research authority on pharmaceutical clinical trials recently reviewed the findings from the 14th International Conference on Alzheimer’s Disease (ICAD 2011/AAIC 2011) July 16-21, 2011, noting that while pharma continues to develop beta amyloid targeting drugs, amyloid targets are moving ahead in terms of biomarkers and early warning for risk of Alzheimer’s.

GNS, Bristol-Myers Squibb to Identify Immuno-Inflammation Biomarkers

GNS Healthcare, Inc., (GNS) the leading healthcare analytics company focused on enabling personalized medicine to improve human health, today announced that it has entered into a collaboration with Bristol Myers-Squibb Company focused on the discovery of novel disease biology and biomarkers in the area of immuno-inflammation. Utilizing its supercomputer-driven REFS (reverse-engineering and forward-simulation) platform, GNS will use clinical and molecular information from a Bristol-Myers Squibb clinical trial to build computer models in a hypothesis-free, unbiased manner that will be simulated to identify key molecular mechanisms. Financial terms of the agreement were not disclosed.

European Medicines Agency Requests Public Comment on Alzheimer’s Biomarkers

The European Medicines Agency (EMA) is requesting public comment on its first qualification opinion regarding a clinical biomarker for use in humans.

OPKO Health Identifies Alzheimer’s Diagnostic Markers, Collaborates with Bristol-Meyers Squibb

Earlier this month, OPKO Health announced the publication (link below) of a powerful method for the identification in small blood samples of disease-specific antibodies that can serve as diagnostic biomarkers. They also reported on the discovery of two antibodies unique to patients with Alzheimer’s disease.

New Test May Help Patients With RA Avoid Useless Treatment

A network of rheumatology practitioners is teaming up with several pharmaceutical companies to evaluate a new biomarker screening test that might help identify patients with rheumatoid arthritis (RA) who are unlikely to benefit from treatment with antitumor necrosis factor-alpha (anti-TNF) agents. This could help clinicians avoid exposing individual patients to adverse effects from drugs unlikely to be effective, reduce healthcare costs, and quickly identify patients who would be candidates for other regimens or for clinical trials of new agents.